Franklin Biotechnology Discovery Fund is a registered fund series of Franklin Strategic Series (series S000006882). Net assets $1.0B as of 2026-04-30.
Showing 15 of 113 holdings by value.
| Holding | Ticker | Value | % of fund |
|---|---|---|---|
| Jazz Pharmaceuticals plc | — | $57.5M | 554.73% |
| Amgen, Inc. | — | $49.2M | 474.51% |
| Gilead Sciences, Inc. | — | $48.3M | 466.03% |
| Regeneron Pharmaceuticals, Inc. | — | $43.1M | 416.45% |
| Vertex Pharmaceuticals, Inc. | — | $41.6M | 401.96% |
| Argenx SE | — | $38.3M | 369.45% |
| Franklin Institutional U.S. Government Money Market Fund | — | $31.6M | 305.28% |
| Franklin Institutional U.S. Government Money Market Fund | — | $30.7M | 296.44% |
| Ascendis Pharma A/S | — | $29.8M | 287.26% |
| Insmed, Inc. | — | $29.2M | 282.02% |
| Revolution Medicines, Inc. | — | $29.2M | 281.61% |
| Praxis Precision Medicines, Inc. | — | $26.0M | 250.59% |
| Dianthus Therapeutics, Inc. | — | $23.8M | 229.50% |
| Guardant Health, Inc. | — | $21.7M | 209.28% |
| Mirum Pharmaceuticals, Inc. | — | $20.9M | 202.13% |
| Report date | Net assets |
|---|---|
| 2026-04-30 | $1.0B |
| 2026-01-31 | $1.0B |
| 2025-10-31 | $954.1M |
| 2025-07-31 | $726.9M |
| 2025-04-30 | $707.7M |
| 2025-01-31 | $803.2M |
| 2024-10-31 | $896.7M |
| 2024-07-31 | $941.1M |